The development of the OCLN recombinant monoclonal antibody is carried out with utmost precision to ensure its quality and specificity. The process begins with the isolation of B cells from an immunized animal, where the synthesized peptide derived from human OCLN is used as the immunogen. Total RNA is then extracted from these B cells and converted into cDNA through reverse transcription. Using specific primers that target the antibody constant regions, the OCLN antibody genes are amplified and inserted into an expression vector. This vector is then transfected into host cells to facilitate the production of the OCLN recombinant monoclonal antibody. After a period of cell culture, the antibody is harvested from the supernatant and purified using affinity chromatography, resulting in a highly purified form ready for use. To validate its specificity and functionality, the antibody undergoes comprehensive characterization assays, including ELISA, IHC, and FC analysis, ensuring its accurate binding to human OCLN protein.